We are live on
!
Find out more
BBA
Baker Bros. Advisors Portfolio holdings
AUM
$17.4B
1-Year Est. Return
131.5%
This Fund
S&P 500
This Quarter
Est. Return
+35.46%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$17.1B
AUM Growth
+$3.24B
(+23%)
Cap. Flow
+$452M
Cap. Flow
% of AUM
2.65%
Top 10 Holdings %
Top 10 Hldgs %
74.38%
Holding
100
New
9
Increased
23
Reduced
7
Closed
14
Top Buys
| 1 |
Kymera Therapeutics
KYMR
|
+$135M |
| 2 |
Ionis Pharmaceuticals
IONS
|
+$92.2M |
| 3 |
Praxis Precision Medicines
PRAX
|
+$81.4M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
+$60.9M |
| 5 |
Alkermes
ALKS
|
+$57.5M |
Top Sells
| 1 |
MRUS
Merus
MRUS
|
+$54.1M |
| 2 |
Intellia Therapeutics
NTLA
|
+$47.4M |
| 3 |
Stoke Therapeutics
STOK
|
+$39M |
| 4 |
RNAM
Avidity Biosciences
RNAM
|
+$27.2M |
| 5 |
Vaxcyte
PCVX
|
+$23.1M |
Sector Composition
| 1 | Healthcare | 99.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Cerus
CERS
$615M
| $20.6M | 0.12% |
10,008,345
| – | – |
|
52
Neurogene
NGNE
$780M
| $20.4M | 0.12% |
991,691
| – | – |
|
|
TECX
53
Tectonic Therapeutic
TECX
$657M
| $18.8M | 0.11% |
903,400
+803,400
| +803% | +$14.9M |
|
54
CytomX Therapeutics
CTMX
$797M
| $18.1M | 0.11% |
4,250,826
| – | – |
|
55
Celldex Therapeutics
CLDX
$3B
| $18.1M | 0.11% |
665,370
| – | – |
|
56
Xencor
XNCR
$1.11B
| $16.9M | 0.1% |
1,102,106
| – | – |
|
|
CNTA
57
DELISTED
Centessa Pharmaceuticals
CNTA
| $16.8M | 0.1% |
+670,751
| New | +$17M |
|
58
Xenon Pharmaceuticals
XENE
$6.51B
| $16.6M | 0.1% |
370,208
| – | – |
|
|
SION
59
Sionna Therapeutics
SION
$1.92B
| $16.5M | 0.1% |
400,000
| – | – |
|
|
CTNM
60
Contineum Therapeutics
CTNM
$545M
| $16.2M | 0.1% |
1,420,838
+1,343,168
| +1,729% | +$15.3M |
|
61
Sera Prognostics
SERA
$77.5M
| $16.2M | 0.1% |
5,498,170
| – | – |
|
62
Dyne Therapeutics
DYN
$3.93B
| $15.9M | 0.09% |
+813,449
| New | +$15.4M |
|
|
ALMS
63
Alumis Inc
ALMS
$3.48B
| $15.3M | 0.09% |
1,562,500
| – | – |
|
64
Nuvalent
NUVL
$9.81B
| $14.5M | 0.08% |
143,937
| – | – |
|
65
Pharvaris
PHVS
$2.41B
| $10.4M | 0.06% |
375,000
| – | – |
|
66
Relay Therapeutics
RLAY
$4.16B
| $9.81M | 0.06% |
1,160,117
| – | – |
|
67
Absci
ABSI
$1.73B
| $7.45M | 0.04% |
+2,134,803
| New | +$7.78M |
|
68
Arcus Biosciences
RCUS
$3.56B
| $6.43M | 0.04% |
+270,000
| New | +$5.51M |
|
|
MPLT
69
MapLight Therapeutics
MPLT
$1.72B
| $6.41M | 0.04% |
+364,705
| New | +$6.11M |
|
70
vTv Therapeutics
VTVT
$126M
| $5.93M | 0.03% |
148,314
| – | – |
|
71
Wave Life Sciences
WVE
$1.18B
| $5.85M | 0.03% |
344,063
| – | – |
|
72
Sagimet Biosciences
SGMT
$479M
| $5.64M | 0.03% |
952,996
| – | – |
|
73
Protara Therapeutics
TARA
$230M
| $5.18M | 0.03% |
971,614
+434,782
| +81% | +$2.42M |
|
|
LBRX
74
LB Pharmaceuticals
LBRX
$918M
| $4.45M | 0.03% |
200,000
| – | – |
|
75
Enliven Therapeutics
ELVN
$3.7B
| $4.18M | 0.02% |
271,406
+156,573
| +136% | +$3.12M |
|
Similar funds
MCM
ASRS
PP
CS
SFA
VMPIC
LA
BCIM